Tag: Immunotherapy
-
americans living longer after cancer diagnosis: rising survival rates offer hope
Uplifting Trends in American Cancer Survival New findings about cancer survival in the United States are offering renewed hope to millions. Recent data from the American Cancer Society show that seven out of every ten Americans diagnosed with cancer now survive for at least five years. That figure represents a meaningful improvement in cancer outcomes…
-
NDL2 Nuclear PD-L1 Degrader Shows Promising Preclinical Data for Immunotherapy Resistance
Overview Kazia Therapeutics has announced compelling preclinical and translational data for NDL2, its nuclear PD-L1 degrader. The findings suggest that targeting nuclear PD-L1 could overcome immunotherapy resistance and curb metastatic progression in certain solid tumors. This research positions NDL2 as a potentially transformative approach in cancer immunotherapy, addressing previously unrecognized drivers of disease advancement. What…
-
Kazia Therapeutics Unveils Promising Nuclear PD-L1 Degrader Data (NDL2)
Groundbreaking Findings on Nuclear PD-L1 Kazia Therapeutics has announced compelling preclinical and translational data for its nuclear PD-L1 degrader, NDL2. The findings position nuclear PD-L1 as a previously underappreciated driver of resistance to immunotherapy and a contributor to metastatic progression. By targeting the nuclear pool of PD-L1, NDL2 aims to complement existing therapies that primarily…
-
Kazia Therapeutics Reports Encouraging Early Signals from Paxalisib + Pembrolizumab in Late-Stage Metastatic TNBC
Overview of the Update Kazia Therapeutics (NASDAQ: KZIA) announced an interim clinical update from its ongoing Phase 1b study evaluating paxalisib in combination with pembrolizumab and chemotherapy for patients with late-stage (Stage IV) metastatic triple-negative breast cancer (TNBC). The release underscores encouraging preliminary clinical responses observed to date, reinforcing interest in paxalisib as part of…
-
Kazia Therapeutics Unveils Encouraging Early Responses for Paxalisib in Late-Stage TNBC
Overview of the Phase 1b Study Kazia Therapeutics has announced encouraging preliminary clinical responses from its ongoing Phase 1b trial evaluating paxalisib in combination with pembrolizumab and chemotherapy for patients with late-stage, Stage IV triple-negative breast cancer (TNBC). The study explores paxalisib, an AKT inhibitor, as part of a multi-agent regimen designed to address the…
-
HanchorBio and WuXi Biologics Forge Fusion Protein Partnership
Strategic Alliance to Accelerate Next-Generation Bi- and Multi-Functional Fusion Proteins HanchorBio, Inc. and WuXi Biologics have announced a strategic partnership designed to advance a next-generation pipeline of bi- and multi-functional fusion proteins. The collaboration brings together HanchorBio’s clinical-stage expertise in immunotherapy with WuXi Biologics’ global manufacturing and development capabilities, aiming to accelerate the discovery, optimization,…
-
HanchorBio WuXi Biologics Partnership Advances Proteins
Strategic Partnership Expands Next-Generation Fusion Protein Pipeline HanchorBio, a global clinical-stage biotechnology company focused on next-generation immunotherapies, and WuXi Biologics, a leading contract development and manufacturing organization for biologics, announced a strategic collaboration to accelerate the development of next-generation bifunctional fusion proteins. The alliance aims to advance a robust pipeline targeting oncology and autoimmune diseases,…
-
HanchorBio and WuXi Biologics Forge Strategic Partnership to Accelerate Next-Gen Bi- and Multi-Functional Fusion Protein Pipeline
Strategic Partnership Aims to Accelerate Next-Generation Fusion Protein Programs HanchorBio, Inc., a global clinical-stage biotechnology company focused on next-generation immunotherapies for oncology and autoimmune diseases, and WuXi Biologics, a leading global biopharmaceutical development and manufacturing services provider, today announced a strategic partnership to advance a next-generation bi- and multi-functional fusion protein pipeline. This collaboration is…
-
Cancer Vaccines Enter a New Era of Personalized Immunotherapy
Overview: A Turning Point in Cancer Vaccines For decades, researchers have pursued cancer vaccines as a means to train the immune system to recognize and attack tumors. A comprehensive review from the Icahn School of Medicine at Mount Sinai highlights a pivotal shift: cancer vaccines are moving from generic approaches toward highly personalized immunotherapies. By…
-
Cancer vaccines enter a new era of personalized immunotherapy
A turning point in cancer vaccines Decades of cancer vaccine research are coalescing into a new era of personalized immunotherapy. Led by a comprehensive review from researchers at the Icahn School of Medicine at Mount Sinai, the latest work highlights how advances in genomics, bioinformatics, and immune engineering are enabling vaccines that are tailored to…